Demchenko E Iu, Kulakova N V, Semiglazova T A, Golovacheva A B, Borodulina E V, Udut V V
Eksp Klin Farmakol. 2008 Nov-Dec;71(6):13-5.
Patients with a chronic brain ischemia of stages I-II on the background of hypertension and/or cerebral atherosclerosis are characterized by energy insufficiency of the metabolism, as estimated by the activity of succinate dehydrogenase in peripheral blood lymphocytes. Within the framework of randomized comparative investigation of the efficiency of actovegin and mexidol in the complex therapy of a chronic brain ischemia, positive dynamics in reduction of the clinical semiology, restoration of cognitive processes in the brain, and reduction of the expression of subjective manifestations of the disease is established. On this background, the administration of mexidol led to restoration of the energy exchange due to substrate effects of the Krebs cycle intermediates present in its structure.
在高血压和/或脑动脉粥样硬化背景下处于I-II期慢性脑缺血的患者，通过外周血淋巴细胞中琥珀酸脱氢酶的活性评估，其代谢存在能量不足。在比较阿克托维吉（actovegin）和美西律（mexidol）对慢性脑缺血综合治疗效果的随机对照研究框架内，证实了在减轻临床症状学、恢复大脑认知过程以及减少疾病主观表现方面的积极动态变化。在此背景下，美西律的给药由于其结构中存在的三羧酸循环中间产物的底物效应而导致能量代谢恢复。
